Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Risk

The legacy of general health and science information has long served as a foundation for public understanding of medication risks and benefits. Within this broad context, discussions of bisphosphonate therapies—such as Fosamax—have typically centered on their role in managing bone density disorders, with patient education materials emphasizing adherence and common side effects. As awareness of rare adverse events has grown, the focus has expanded from general clinical guidance to more specific safety considerations. This shift naturally leads to a critical occupational exposure concern: for individuals who manufacture, handle, or administer Fosamax in industrial or healthcare settings, the potential for repeated dermal or inhalational contact introduces a distinct risk profile. Unlike the controlled, intermittent dosing experienced by patients, occupational exposure may involve chronic, low-level contact with the active pharmaceutical ingredient. This raises the question of whether such exposure patterns could contribute to the development of osteonecrosis of the jaw, a condition previously associated primarily with high-dose or long-term therapeutic use. The transition from general health information to occupational risk assessment requires careful consideration of exposure routes, duration, and cumulative dose, without presupposing mechanistic pathways. Thus, the inquiry into Fosamax and osteonecrosis of the jaw causation now extends beyond the patient population to include those whose work brings them into regular contact with this compound.

Bridging to Clinical Evidence

Building on the occupational context, it is essential to examine the clinical evidence linking Fosamax to osteonecrosis of the jaw (ONJ). Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A known adverse effect associated with bisphosphonate therapy, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves pain, swelling, infection, and exposed bone in the mandible or maxilla, often following dental procedures.

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding involves the drug's pharmacology as a bisphosphonate. Bisphosphonates inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jawbone, which has high remodeling rates, this suppression may impair the ability to repair microdamage and respond to local infections or trauma. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique structure and physiology of the jawbone may make it particularly susceptible to the effects of bisphosphonates. The time to onset of ONJ symptoms after starting Fosamax can vary widely, from one day to several months after initiating the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability indicates that individual patient factors, such as dental health and concurrent medications, play a significant role in the development of ONJ. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Trial Data and Post-Marketing Reports

In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as jaw pain or other oral symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse event, its incidence in clinical trial populations may be low. However, post-marketing reports have documented cases of ONJ in patients taking bisphosphonates, including Fosamax. For patients who develop severe symptoms, discontinuation of the drug is recommended, and most patients experience relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This is a key consideration in clinical management, as dental procedures are a common precipitating factor.

Duration of Use and Clinical Management

The optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance reflects the balance between the benefits of fracture reduction and the potential risks of long-term bisphosphonate therapy, including ONJ. In summary, the evidence supports a causal association between Fosamax and osteonecrosis of the jaw, particularly in the presence of risk factors such as invasive dental procedures, cancer, and concomitant therapies. The timeline from exposure to onset can be variable, and the risk may increase with longer duration of use. Clinical management should include careful dental evaluation before and during therapy, and consideration of drug discontinuation for patients at low fracture risk or those undergoing invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is the evidence that Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate known to be associated with osteonecrosis of the jaw (ONJ). The FDA label lists ONJ as a known adverse effect, and post-marketing reports have documented cases. Mechanistically, bisphosphonates suppress bone turnover, and the jawbone's high remodeling rate makes it susceptible. Risk factors include invasive dental procedures, cancer, and long-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long does it take for Fosamax to cause jaw problems?

The time to onset of ONJ symptoms after starting Fosamax can vary widely, from one day to several months after initiating the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Individual factors such as dental health and concurrent medications influence this timeline.

What should I do if I have jaw pain while taking Fosamax?

If you develop severe symptoms such as jaw pain, swelling, or exposed bone, consult your healthcare provider. Discontinuation of Fosamax is recommended for severe symptoms, and most patients experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A dental evaluation is also advised.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.